Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
March 21 2024 - 1:00PM
Information on the Total Number of Voting Rights (Denominator)
following Conversion Notices from Atlas
Information on the Total Number of Voting
Rights (Denominator) following Conversion Notices from
Atlas
Atlas Special Opportunities, LLC has converted 6
convertible bonds in Oxurion resulting in a EUR 150,000 capital
increase. This is part of Atlas Special Opportunities, LLC’s EUR 20
million Capital Commitment1 that will allow Oxurion to focus on
developing innovative therapeutics to preserve the vision of
elderly people, targeting potential market opportunities of USD 3-6
billion.
Leuven, BELGIUM – 21 March, 2024 – 07.00
PM CET – In accordance with article 15 of the Belgian Act
of May 2, 2007 on the disclosure of major participations in issuers
of which shares are admitted to trading on a regulated market and
regarding miscellaneous provisions, Oxurion NV (Euronext Brussels:
OXUR) (the “Company” or “Oxurion”), announces the below
information, following the issuance of 1,630,434,782 new ordinary
shares on March 20, 2024, for a total amount of EUR 150,000
pursuant to the Capital Commitment entered into with Atlas Special
Opportunities, LLC.
Following completion of capital increase through
the conversion of the convertible bonds, the total number of shares
issued by Oxurion amounts to 7,384,386,505 outstanding ordinary
shares carrying voting rights (compared to 5,753,951,723
outstanding ordinary shares previously). This number will be used
as the denominator for the calculation of the percentages of
shareholdings.
Therefore, Oxurion publishes the following
updated information:
|
|
84,206,161.32 |
- Total number of securities with
voting rights (all ordinary shares)
|
7,384,386,505 |
- Total number of ordinary shares (=
denominator)
|
7,384,386,505 |
- Number of outstanding, granted
rights to subscribe to securities carrying voting rights not yet
issued (excluding any shares resulting (a) from the potential
conversion of any convertibles bonds issued on December 20, 2021 to
the benefit of Kreos Capital VI (UK) Limited, Pontifax Medison
Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. or
(b) from the exercise of any subscription rights issued by the
Company to the benefits of employees, consultants or directors of
the Company (as they are both currently significantly
out-of-the-money):
|
|
- 310 convertible bonds issued on
March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August
10, 2023, September 15, 2023, October 20, 2023, October 24, 2023,
November 15, 2023 and November 15, 2023, January 9, 2024,February
2, 2024 and March 4, 2024, entitling its holder, Atlas Special
Opportunities, LLC, to subscribe to a total number of securities
carrying voting rights (all ordinary shares) in accordance with the
terms and conditions of these convertible bonds pursuant to the
Subscription Agreement entered into between the Company and Atlas
Special Opportunities, LLC on March 1, 2023, as amended on
September 10, 2023 and December 22, 2023.
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in
developing next-generation standard of care ophthalmic therapies
for the treatment of retinal disease. Oxurion is based in Leuven,
Belgium. More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
Please contact for additional information:
|
Oxurion NVPascal GhosonChief Executive
Officerpascal.ghoson@oxurion.com |
Backstage CommunicationJurgen
VluijmansPartnerjurgen@backstagecom.be |
1 Press release Oxurion, 02/03/2023
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Apr 2023 to Apr 2024
